SepsisnSePNCT03777670
nSeP: Detecting Neonatal Sepsis by Immune-Metabolic Network Analysis
An observational study of Sepsis, run by Cardiff and Vale University Health Board at 1 site in United Kingdom.
Trial summary
Diagnosis of neonatal sepsis remains a challenge due to non-specific signs and diagnostic inaccuracies. Studies have shown that this could lead to overdiagnosis and overuse of antibiotic treatment, with potential long-term adverse effects. Read more about this study
- Who is it for?
- Ages Up to 4 months
- Conditions the study is for
- Sepsis
- What is being tested?
- Blood test
- How many people
- 1,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 Feb 2020to 28 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 4 months
- All sexes
- Child
Study population: Newborn infants in the neonatal unit with a suspicion of sepsis
Who may be able to join
- Screened with traditional tests (full-blood count [FBC], inflammatory markers like C-reactive protein [CRP], and blood-culture) for suspected sepsis (including non-infective inflammatory conditions) and started on antibiotics - potential cases.
- Being sampled for non-septic conditions (bloods sampling for routine monitoring, jaundice, hypoglycaemia, etc.) - controls.
- Informed consent from parents to use blood and stool samples (initial sample and 24-hour sample) and clinical data for study.
Who cannot join
- Language and communication issues, which will make it difficult to explain study and request informed consent.
- When an infant has a high chance of mortality in the next 24-hours.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
University Hospital of Wales
Cardiff, South Glamorgan, CF14 4XN
Mallinath Chakraborty, PhD, +44 2920 742276, chakrabortym@cardiff.ac.uk
About this study
Official title: Detecting Neonatal Sepsis by Immune-Metabolic Network Analysis
Diagnosis of neonatal sepsis remains a challenge due to non-specific signs and diagnostic inaccuracies. Studies have shown that this could lead to overdiagnosis and overuse of antibiotic treatment, with potential long-term adverse effects.
A systems approach towards diagnosing neonatal sepsis has been shown to have high accuracy in initial studies. This study aims to recruit a large validation cohort to confirm findings.
Read the detailed description
Several studies have shown that changes in host gene expression may occur pre- symptomatically in response to infection in any part of the body, with the continuous interaction between blood and tissue allowing blood cells to act as biosensors for the changes (Manger and Relman, 2000, Liew et al., 2006). Genome wide analysis reveals coordinate expression that develop networks causally linked through pathways.
Earlier studies from our group investigating optimal methods for the sampling and extraction of neonatal whole transcription products (RNA) demonstrated the first feasibility studies for using genome wide RNA analysis as a methodological approach for identifying host biomarkers of infection and vaccination in early life (Smith et al., 2007, Flanagan et al., 2013). The sampling methods were further refined in 2015 with the development of a single drop methodology that has been extensively tested in a wide range of settings including the collection of neonatal samples in the home, at the point of Guthrie testing by mid-wives. Details of these methods have been recently submitted to the Nature Protocols journal. Further, we conducted early on virtual clinical trials using a super computing framework that simulated several 100,000 neonatal whole blood samples for predicting infection (Khondoker et al., 2010). Those investigations showed the requirement for multiple markers and ideally in discrete biological pathways underpinning causality (Khondoker et al., 2010, Watterson and Ghazal, 2010). Those investigations provided a strong foundation for initiating a case-control of neonatal sepsis (Dickinson et al., 2015). Accordingly, we were the first group to publish studies investigating the systemic immune response in neonates to sepsis by measuring the activity of all known human genes (Smith et al Nature comm. 2014). These computationally intensive investigations led to uncovering, for the first time, the pathway biology underlying neonatal sepsis with blood samples taken at the first clinical signs of suspecting an infection. A combination of machine learning, statistical and deep pathway biology analyses led to the identification of a 52-gene panel of biologically connected network modules. The modules comprise three central pathways, innate-immune or inflammatory, adaptive-immune and unexpectedly metabolic. The expression levels of particular combinations of biomarkers, and specifically those of a pathway previously unconnected to immune responses, gives an unusually high diagnostic quality. Despite patient heterogeneity, the 52-node dual biomarker network had greater than 99% accuracy for detecting bacterial infection with 100% sensitivity showing superior performance to previously characterised markers. Furthermore, these specific combinations of biomarkers allowed the detection of neonatal sepsis in samples which had displayed blood-culture negative results, illustrating the specific diagnostic benefits of the particular combinations of biomarkers. The unexpectedly high accuracy and sensitivity values could not have resulted from the investigation of any of the individual biomarkers alone, nor could they have been predicted. A critical part of these findings is the requirement of metabolic pathways for increasing both sensitivity and specificity. A subset of the metabolic markers encompass ligands (specifically small and medium chain fatty acids) that are derived from microbial metabolism, in particular from commensals and which are reflected in the faecal microbiome. To date these studies provide a proof of concept but need independent confirmatory studies as well as investigating specificity against non-bacterial (viral and fungal) infections and sterile inflammation. The urgent unmet medical question is whether predictive host pathways of infection can be used to first identify whether a patient is infected at or before clinical presentation and, to further discriminate between the type of infection (in particular bacterial or viral) and predictability of sepsis.
- Conditions
- Sepsis
- Being tested
- Blood test
- Keywords
- Newborn
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood testDiagnostic test
Drop of blood for RNA and metabolic analysis
| Study group | Role | What they receive |
|---|---|---|
| Cases | Infants with suspected sepsis Receives: Diagnostic Test: Blood test | |
| Controls | Infants with no suspicion of sepsis Receives: Diagnostic Test: Blood test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sepsis
Immune signature of sepsis
Measured: 5-years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2018
- Study start26 Feb 2020
- Primary completion28 Feb 2023 (estimated)
- Study completion28 Feb 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cardiff and Vale University Health Board
- Sponsor type
- Other government
- Collaborators
- Cardiff University
- Responsible party
- Principal investigator, Mallinath Chakraborty, Cardiff and Vale University Health Board
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03777670
- Sponsor's protocol ID
- 248404
- Acronym
- nSeP
- Status last verified
- Apr 2020
- First submitted
- 13 Dec 2018
- Last updated
- 7 Apr 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chakraborty M, Rodrigues PRS, Watkins WJ, Hayward A, Sharma A, Hayward R, Smit E, Jones R, Goel N, Asokkumar A, Calvert J, Odd D, Morris I, Doherty C, Elliott S, Strang A, Andrews R, Zaher S, Sharma S, Bell S, Oruganti S, Smith C, Orme J, Edkins S, Craigon M, White D, Dantoft W, Davies LC, Moet L, McLaren JE, Clarkstone S, Watson GL, Hood K, Kotecha S, Morgan BP, O'Donnell VB, Ghazal P. nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study. BMJ Open. 2021 Dec 30;11(12):e050100. doi: 10.1136/bmjopen-2021-050100.
PubMed 37010923
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Detecting Neonatal Sepsis by Immune-Metabolic Network Analysis
- ClinicalTrials.gov ID
- NCT03777670
- Acronym / sponsor ID
- nSeP / 248404
- Conditions
- Sepsis
- Keywords
- Newborn
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Cardiff and Vale University Health BoardOther government
- Collaborators
- Cardiff University
- Study start
- 26 Feb 2020 (actual)
- Primary completion
- 28 Feb 2023 (estimated)
- Study completion
- 28 Feb 2024 (estimated)
- First posted
- 17 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diagnosis of neonatal sepsis remains a challenge due to non-specific signs and diagnostic inaccuracies. Studies have shown that this could lead to overdiagnosis and overuse of antibiotic treatment, with potential long-term adverse effects.
A systems approach towards diagnosing neonatal sepsis has been shown to have high accuracy in initial studies. This study aims to recruit a large validation cohort to confirm findings.
Detailed description
Several studies have shown that changes in host gene expression may occur pre- symptomatically in response to infection in any part of the body, with the continuous interaction between blood and tissue allowing blood cells to act as biosensors for the changes (Manger and Relman, 2000, Liew et al., 2006). Genome wide analysis reveals coordinate expression that develop networks causally linked through pathways.
Earlier studies from our group investigating optimal methods for the sampling and extraction of neonatal whole transcription products (RNA) demonstrated the first feasibility studies for using genome wide RNA analysis as a methodological approach for identifying host biomarkers of infection and vaccination in early life (Smith et al., 2007, Flanagan et al., 2013). The sampling methods were further refined in 2015 with the development of a single drop methodology that has been extensively tested in a wide range of settings including the collection of neonatal samples in the home, at the point of Guthrie testing by mid-wives. Details of these methods have been recently submitted to the Nature Protocols journal. Further, we conducted early on virtual clinical trials using a super computing framework that simulated several 100,000 neonatal whole blood samples for predicting infection (Khondoker et al., 2010). Those investigations showed the requirement for multiple markers and ideally in discrete biological pathways underpinning causality (Khondoker et al., 2010, Watterson and Ghazal, 2010). Those investigations provided a strong foundation for initiating a case-control of neonatal sepsis (Dickinson et al., 2015). Accordingly, we were the first group to publish studies investigating the systemic immune response in neonates to sepsis by measuring the activity of all known human genes (Smith et al Nature comm. 2014). These computationally intensive investigations led to uncovering, for the first time, the pathway biology underlying neonatal sepsis with blood samples taken at the first clinical signs of suspecting an infection. A combination of machine learning, statistical and deep pathway biology analyses led to the identification of a 52-gene panel of biologically connected network modules. The modules comprise three central pathways, innate-immune or inflammatory, adaptive-immune and unexpectedly metabolic. The expression levels of particular combinations of biomarkers, and specifically those of a pathway previously unconnected to immune responses, gives an unusually high diagnostic quality. Despite patient heterogeneity, the 52-node dual biomarker network had greater than 99% accuracy for detecting bacterial infection with 100% sensitivity showing superior performance to previously characterised markers. Furthermore, these specific combinations of biomarkers allowed the detection of neonatal sepsis in samples which had displayed blood-culture negative results, illustrating the specific diagnostic benefits of the particular combinations of biomarkers. The unexpectedly high accuracy and sensitivity values could not have resulted from the investigation of any of the individual biomarkers alone, nor could they have been predicted. A critical part of these findings is the requirement of metabolic pathways for increasing both sensitivity and specificity. A subset of the metabolic markers encompass ligands (specifically small and medium chain fatty acids) that are derived from microbial metabolism, in particular from commensals and which are reflected in the faecal microbiome. To date these studies provide a proof of concept but need independent confirmatory studies as well as investigating specificity against non-bacterial (viral and fungal) infections and sterile inflammation. The urgent unmet medical question is whether predictive host pathways of infection can be used to first identify whether a patient is infected at or before clinical presentation and, to further discriminate between the type of infection (in particular bacterial or viral) and predictability of sepsis.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases | – | Diagnostic Test: Blood testInfants with suspected sepsis |
| Controls | – | Diagnostic Test: Blood testInfants with no suspicion of sepsis |
Who may qualify
- Ages
- Up to 4 months
- Sex
- All
- Age groups
- Child
- Study population
- Newborn infants in the neonatal unit with a suspicion of sepsis
Key inclusion criteria (3 listed)
- Screened with traditional tests (full-blood count [FBC], inflammatory markers like C-reactive protein [CRP], and blood-culture) for suspected sepsis (including non-infective inflammatory conditions) and started on antibiotics - potential cases.
- Being sampled for non-septic conditions (bloods sampling for routine monitoring, jaundice, hypoglycaemia, etc.) - controls.
- Informed consent from parents to use blood and stool samples (initial sample and 24-hour sample) and clinical data for study.
Key exclusion criteria (2 listed)
- Language and communication issues, which will make it difficult to explain study and request informed consent.
- When an infant has a high chance of mortality in the next 24-hours.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood testDrop of blood for RNA and metabolic analysis | Diagnostic test | Cases, Controls |
Primary outcome
Sepsis
Time frame: 5-years
Immune signature of sepsis
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2020.
- Derived from this study: PubMed 37010923Chakraborty M, Rodrigues PRS, Watkins WJ, Hayward A, Sharma A, Hayward R, Smit E, Jones R, Goel N, Asokkumar A, Calvert J, Odd D, Morris I, Doherty C, Elliott S, Strang A, Andrews R, Zaher S, Sharma S, Bell S, Oruganti S, Smith C, Orme J, Edkins S, Craigon M, White D, Dantoft W, Davies LC, Moet L, McLaren JE, Clarkstone S, Watson GL, Hood K, Kotecha S, Morgan BP, O'Donnell VB, Ghazal P. nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study. BMJ Open. 2021 Dec 30;11(12):e050100. doi: 10.1136/bmjopen-2021-050100.
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis, run by Cardiff and Vale University Health Board at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Peter Ghazal, PhD (29207 44721, ghazalp@cardiff.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sepsis (time frame: 5-years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03777670, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2020.